eGenesis Secures $191 Million to Advance Gene-Edited Pig Kidney for Human Transplant
• eGenesis has raised $191 million in Series D financing to advance its gene-edited pig kidney program, EGEN-2784, towards human clinical trials.
• The funding will support the expansion of eGenesis's production capabilities and further development of its pipeline programs focused on other organs.
• eGenesis achieved the world's first successful transplant of a genetically modified porcine kidney into a living human patient in March 2024.
• The company's technology addresses cross-species molecular incompatibilities and viral risks through advanced genetic engineering techniques.
© Copyright 2025. All Rights Reserved by MedPath